The pathobiology of diabetic vascular complications-cardiovascular and kidney disease

被引:64
作者
Gray, Stephen P. [1 ]
Jandeleit-Dahm, Karin [1 ]
机构
[1] Baker IDI Heart & Diabet Res Inst, Diabet Complicat Div, Melbourne, Vic 8008, Australia
来源
JOURNAL OF MOLECULAR MEDICINE-JMM | 2014年 / 92卷 / 05期
基金
澳大利亚国家健康与医学研究理事会;
关键词
Diabetes; Oxidative stress; RAS; AGEs; Nephropathy; Cardiovascular disease; GLYCATION END-PRODUCTS; NADPH OXIDASE 5; CONVERTING ENZYME-INHIBITION; ENDOTHELIAL GROWTH-FACTOR; SMOOTH-MUSCLE-CELLS; II TYPE-2 RECEPTORS; ALL-CAUSE MORTALITY; CROSS-LINK BREAKER; HIGH-DOSE THIAMINE; ANGIOTENSIN-II;
D O I
10.1007/s00109-014-1146-1
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
With the increasing incidence of obesity and type 2 diabetes, it is predicted that more than half of Americans will have diabetes or pre-diabetes by 2020. Diabetic patients develop vascular complications at a much faster rate in comparison to non-diabetic individuals, and cardiovascular risk is increased up to tenfold. With the increasing incidence of diabetes across the world, the development of vascular complications will become an increasing medical burden. Diabetic vascular complications affect the micro- and macro-vasculature leading to kidney disease often requiring dialysis and transplantation or cardiovascular disease increasing the risk for myocardial infarction, stroke and amputations as well as leading to premature mortality. It has been suggested that many complex pathways contribute to the pathobiology of diabetic complications including hyperglycaemia itself, the production of advanced glycation end products (AGEs) and interaction with the receptors for AGEs such as the receptor for advanced glycation end products (RAGE), as well as the activation of vasoactive systems such as the renin-angiotensin aldosterone system (RAAS) and the endothelin system. More recently, it has been hypothesised that reactive oxygen species derived from NAD(P)H oxidases (Nox) may represent a common downstream mediator of vascular injury in diabetes. Current standard treatment of care includes the optimization of blood glucose and blood pressure usually including inhibitors of the renin-angiotensin system. Although these interventions are able to delay progression, they fail to prevent the development of complications. Thus, there is an urgent medical need to identify novel targets in diabetic vascular complications which may include the blockade of Nox-derived ROS formation, as well as blockade of AGE formation and inhibitors of RAGE activation. These strategies may provide superior protection against the deleterious effects of diabetes on the vasculature.
引用
收藏
页码:441 / 452
页数:12
相关论文
共 173 条
[21]   Poor prognosis of young adults with type 1 diabetes - A longitudinal study [J].
Bryden, KS ;
Dunger, DB ;
Mayou, RA ;
Peveler, RC ;
Neil, HAW .
DIABETES CARE, 2003, 26 (04) :1052-1057
[22]   ACE2, a new regulator of the renin-angiotensin system [J].
Burrell, LM ;
Johnston, CI ;
Tikellis, C ;
Cooper, ME .
TRENDS IN ENDOCRINOLOGY AND METABOLISM, 2004, 15 (04) :166-169
[23]   The vascular NAD(P)H oxidases as therapeutic targets cardiovascular diseases [J].
Cai, H ;
Griendling, KK ;
Harrison, DG .
TRENDS IN PHARMACOLOGICAL SCIENCES, 2003, 24 (09) :471-478
[24]   NAD(P)H oxidase-dependent self-propagation of hydrogen peroxide and vascular disease [J].
Cai, H .
CIRCULATION RESEARCH, 2005, 96 (08) :818-822
[25]   Inhibitors of advanced glycation end product formation and neurovascular dysfunction in experimental diabetes [J].
Cameron, NE ;
Gibson, TM ;
Nangle, MR ;
Cotter, MA .
MAILLARD REACTION: CHEMISTRY AT THE INTERFACE OF NUTRITION, AGING, AND DISEASE, 2005, 1043 :784-792
[26]   Irbesartan but not amlodipine suppresses diabetes-associated atherosclerosis [J].
Candido, R ;
Allen, TJ ;
Lassila, M ;
Cao, ZM ;
Thallas, V ;
Cooper, ME ;
Jandeleit-Dahm, KA .
CIRCULATION, 2004, 109 (12) :1536-1542
[27]   A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes [J].
Candido, R ;
Forbes, JM ;
Thomas, MC ;
Thallas, V ;
Dean, RG ;
Burns, WC ;
Tikellis, C ;
Ritchie, RH ;
Twigg, SM ;
Cooper, ME ;
Burrell, LM .
CIRCULATION RESEARCH, 2003, 92 (07) :785-792
[28]   Prevention of accelerated atherosclerosis by angiotensin-converting enzyme inhibition in diabetic apolipoprotein E-deficient mice [J].
Candido, R ;
Jandeleit-Dahm, KA ;
Cao, ZM ;
Nesteroff, SP ;
Burns, WC ;
Twigg, SM ;
Dilley, RJ ;
Cooper, ME ;
Allen, TJ .
CIRCULATION, 2002, 106 (02) :246-253
[29]   Effects of ANG II type 1 and 2 receptors on oxidative stress, renal NADPH oxidase, and SOD expression [J].
Chabrashvili, T ;
Kitiyakara, C ;
Blau, J ;
Karber, A ;
Aslam, S ;
Welch, WJ ;
Wilcox, CS .
AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY, 2003, 285 (01) :R117-R124
[30]   Prevention of arterial stiffening by pyridoxamine in diabetes is associated with inhibition of the pathogenic glycation on aortic collagen [J].
Chang, Kuo-Chu ;
Liang, Jin-Tung ;
Tsai, Pei-Shan ;
Wu, Ming-Shiou ;
Hsu, Kwan-Lih .
BRITISH JOURNAL OF PHARMACOLOGY, 2009, 157 (08) :1419-1426